Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Tecentriq & Avastin Atezolizumab & Bevacizumab Hepatocellular Carcinoma (HCC) Reimburse with clinical criteria and/or conditions Complete
Tecfidera Dimethyl fumarate Multiple sclerosis, relapsing-remitting List with criteria/condition Complete
Technivie Ombitasvir/ paritaprevir/ ritonavir Hepatitis C, chronic List with clinical criteria and/or conditions Complete
Tecvayli teclistamab Relapsed or refractory multiple myeloma Reimburse with clinical criteria and/or conditions Complete
Tegsedi inotersen hereditary transthyretin amyloidosis Reimburse with clinical criteria and/or conditions Complete
Telzir Fosamprenavir calcium HIV infection List in a similar manner to other drugs in class Complete
Tepmetko tepotinib Locally advanced or metastatic non-small cell lung cancer Do not reimburse Complete
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete
Tezspire tezepelumab Asthma Reimburse with clinical criteria and/or conditions Complete
Thelin Sitaxsentan sodium Pulmonary arterial hypertension (WHO class II and III) Do not list Complete